Nattokinase, first found by Dr. Hiroyuki Sumi in 1980, is a potent fibrinolytic enzyme
extracted from Natto, a popular soybean fermented food in Japan. It was confirmed that oral
administration of nattokinase (or natto) produced a mild and frequent enhancement of the
fibrinolytic activity in the plasma as indicated by the fibrinolytic parameters and the
production of tissue plasminogen activator. Other studies also showed a reduction in lipid
peroxidation and improvement of lipid metabolism. Short-term effect (less then 10 days) of
oral administration of nattokinase on both animal and human subjects has been studied and
reported. However, whether nattokinase possesses a beneficial effect to dyslipidemic patients
remains unclear. The aim of this study is to investigate the long-term effect (six month) of
the mono and multiple formulae of nattokinase, change of BP, lipid and fibrinolytic factors
from baseline and 6 months on dyslipidemic patients.